NVO
Price
$40.41Alerts
Change
-$1.20 (-2.88%)
Updated
Nov 17, 11:53 AM (EDT)
Capitalization
178.04B
78 days until earnings call
Intraday BUY SELL Signals
TECH
Price
$72.69Alerts
Change
-$0.10 (-0.14%)
Updated
Nov 17, 04:30 PM (EDT)
Capitalization
11.41B
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVO vs TECH

NVO vs TECH Comparison Chart in %
View a ticker or compare two or three
VS
NVO vs. TECH commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Hold and TECH is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NVO with price predictions
Nov 16, 2026

NVO in upward trend: 10-day moving average moved above 50-day moving average on November 11, 2026

The 10-day moving average for NVO crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on NVO as a result. In 55 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.

NVO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 203 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 161 of 255 cases where NVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Bearish Trend Analysis

The 10-day RSI Indicator for NVO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 24 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 72 cases where NVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

NVO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (-1.421). P/E Ratio (1.534) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.046) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.

A.I.Advisor
a Summary for TECH with price predictions
Nov 16, 2026

Momentum Indicator for TECH turns positive, indicating new upward trend

TECH saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 63 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for TECH just turned positive on November 09, 2026. Looking at past instances where TECH's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.

Following a +0.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in 190 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 94 of 231 cases where TECH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

TECH broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.414) is normal, around the industry mean (3.586). TECH has a moderately high P/E Ratio (62.205) as compared to the industry average of (-1.188). Projected Growth (PEG Ratio) (2.110) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (9.346) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
NVO vs TECH: Fundamental Ratings
NVO
TECH
OUTLOOK RATING
1..100
2476
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1974
PRICE GROWTH RATING
1..100
5617
P/E GROWTH RATING
1..100
9790
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVO's Valuation (66) in the Pharmaceuticals Major industry is in the same range as TECH (94) in the Biotechnology industry. This means that NVO’s stock grew similarly to TECH’s over the last 12 months.

NVO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as TECH (100) in the Biotechnology industry. This means that NVO’s stock grew similarly to TECH’s over the last 12 months.

NVO's SMR Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for TECH (74) in the Biotechnology industry. This means that NVO’s stock grew somewhat faster than TECH’s over the last 12 months.

TECH's Price Growth Rating (17) in the Biotechnology industry is somewhat better than the same rating for NVO (56) in the Pharmaceuticals Major industry. This means that TECH’s stock grew somewhat faster than NVO’s over the last 12 months.

TECH's P/E Growth Rating (90) in the Biotechnology industry is in the same range as NVO (97) in the Pharmaceuticals Major industry. This means that TECH’s stock grew similarly to NVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVOTECH
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
54%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 5 days ago
66%
Declines
ODDS (%)
Bearish Trend 21 days ago
67%
Bearish Trend 7 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
41%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (NVO: $41.60 vs. TECH: $72.79)
Brand notoriety: NVO and TECH are both not notable
NVO represents the Pharmaceuticals: Major, while TECH is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVO: 119% vs. TECH: 113%
Market capitalization -- NVO: $178.04B vs. TECH: $11.41B
NVO [@Pharmaceuticals: Major] is valued at $178.04B. TECH’s [@Biotechnology] market capitalization is $11.41B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVO’s FA Score shows that 1 FA rating(s) are green while TECH’s FA Score has 1 green FA rating(s).

  • NVO’s FA Score: 1 green, 4 red.
  • TECH’s FA Score: 1 green, 4 red.
According to our system of comparison, NVO is a better buy in the long-term than TECH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVO’s TA Score shows that 5 TA indicator(s) are bullish while TECH’s TA Score has 4 bullish TA indicator(s).

  • NVO’s TA Score: 5 bullish, 4 bearish.
  • TECH’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NVO is a better buy in the short-term than TECH.

Price Growth

NVO (@Pharmaceuticals: Major) experienced а +0.53% price change this week, while TECH (@Biotechnology) price change was +0.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.62%. For the same industry, the average monthly price growth was -0.24%, and the average quarterly price growth was +4.35%.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.73%. For the same industry, the average monthly price growth was -7.91%, and the average quarterly price growth was -21.89%.

Reported Earning Dates

NVO is expected to report earnings on Feb 03, 2027.

TECH is expected to report earnings on Feb 02, 2027.

Industries' Descriptions

@Pharmaceuticals: Major (-2.62% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (-9.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been loosely correlated with TECH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NVO jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-0.07%
TECH - NVO
36%
Loosely correlated
-0.01%
GMAB - NVO
35%
Loosely correlated
+0.39%
NVS - NVO
30%
Poorly correlated
-0.19%
AXON - NVO
29%
Poorly correlated
-2.85%
IMTX - NVO
29%
Poorly correlated
-3.44%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PAVM1.750.12
+7.36%
PAVmed Inc
MPB34.98-0.30
-0.85%
Mid Penn Bancorp
AVNT43.97-0.69
-1.55%
Avient Corp
GPRO0.61-0.02
-3.38%
GoPro
RBLX46.12-3.79
-7.59%
Roblox Corp